clinical trial · NCT04074512
Copper Histidinate Treatment for Menkes Disease
Sentynl Therapeutics, Inc.·—·approved for marketing
Menkes Diseasecopper histidinate
brief summary
This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
started
—
primary completion
—
completion
—
last updated
Mar 2, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol